top stories

No­vo Nordisk's first quar­ter in four words: Pills, pric­ing, pay­ments and pres­sure

1 hour ago
Pharma

Bay­er dips toes back in­to phar­ma M&A to buy Per­fuse Ther­a­peu­tics

37 minutes ago
Deals

Cell­Cen­tric rais­es $220M to get mul­ti­ple myelo­ma pill to mar­ket

33 minutes ago
Financing
Startups

In­ter­cep­t's next-gen FXR ag­o­nist fails Phase 2 in lat­est set­back for Ital­ian-owned phar­ma

16 hours ago
R&D

Latest

Pfiz­er's Al­bert Bourla on mega-merg­er prospects: 'No'

17 hours ago
Deals
R&D

BioN­Tech to scale down man­u­fac­tur­ing, over 1,800 jobs on the line

18 hours ago
People
Pharma

Pars­ley Health goes in-net­work na­tion­wide

19 hours ago
Health Tech

Sec­ond life for a gene ther­a­py; Take­da pass­es Phase 2/3 test; UK can­cer biotech's $83M raise

19 hours ago
News Briefing

Swiss man­u­fac­tur­ing, biotech in­dus­try so far un­fazed by geopol­i­tics

20 hours ago
Pharma
Manufacturing

Pfiz­er cuts fi­nal Tril­li­um-re­lat­ed pro­gram, but R&D spend jumps on can­cer, obe­si­ty stud­ies

20 hours ago
R&D
Pharma
see latest stream
Financing

Ex­clu­sive: One can­cer sur­vivor's su­per poop is be­hind mi­cro­bio­me star­tup's $48M raise

21 hours ago

Wind­ward Bio gets $165M to take Chi­na-de­rived drug in­to Phase 3 asth­ma tri­al

Yesterday

Q&A: Sea­port CEO and CSO on learn­ing from Karuna and the fu­ture of CNS re­search

4 days ago
Startups

Biotech has a new com­pa­ny mod­el: A small team, a big check and a few Chi­nese as­sets

Yesterday

MPM has col­lect­ed three Chi­na drugs so far for its ‘best of both worlds’ strat­e­gy

Last week

De­vot­ed Health’s 2025 rev­enue slips in tur­bu­lent Medicare Ad­van­tage mar­ket

Last week
Deals

Up­dat­ed: Madri­gal ex­tends MASH deal streak with Ar­row­head drug that J&J did­n't want

22 hours ago

UCB bets $2B on Can­did's T cell en­gager am­bi­tions

2 days ago

Ace­lyrin founder Shao-Lee Lin emerges at Cue, as it be­comes lat­est to li­cense from Chi­na

4 days ago
Signal

Biotech stocks are on a tear again: Sig­nal In­sights

3 weeks ago

Where does bio­phar­ma go from here?

3 weeks ago

Chi­na is go­ing af­ter the world's most ex­pen­sive drugs: End­points Sig­nal

Last month

In FocusSee all

Bris­tol My­ers reach­es a cross­roads as a make-or-break year takes shape

6 days ago
R&D
Pharma

Ex­clu­sive: UC Berke­ley start­up bets on jump­ing genes for GLP-1 gene ther­a­py

Last week
Cell/Gene Tx
GLP-1 drugs

No­var­tis built a big busi­ness around de­liv­er­ing ra­dioac­tive can­cer treat­ments. Can a gener­ic com­pete?

Last week
Pharma
Manufacturing

How phar­ma is cap­i­tal­iz­ing on the sud­den re­vival and suc­cess of an old asth­ma drug

Last month
R&D
Discovery

Endpoints Standouts

Will CRISPR mat­ter?

Last year
R&D
Special

Big am­bi­tions at Mer­ck and As­traZeneca — along with a few gi­ant pit­falls — re­shape top ranks of the R&D 15

Last year
Bioregnum
R&D

Il­lu­mi­na was built on DNA. Its fu­ture could be bi­ol­o­gy’s next big wave

Last year
In Focus
Diagnostics

Where the mon­ey is: The top 100 ven­ture in­vestors in biotech

Last year
Financing
Bioregnum

Peer review See all

May
1

Boehringer ap­points phar­ma vet­er­an for cor­po­rate af­fairs post; Blue­Rock CSO heads for the ex­it

Apr
24

Pfiz­er’s strat­e­gy chief An­drew Baum steps down; Helus Phar­ma swaps out CEO af­ter two months

Apr
17

No­var­tis' Vas Narasimhan heads to An­throp­ic's board; Met­sera alum joins Struc­ture as COO

Apr
10

Novo's dou­ble de­par­tures: As GLP-1 lu­mi­nary re­tires, an obe­si­ty leader goes to Boehringer In­gel­heim

Apr
2

Lil­ly's chief tech­nol­o­gy of­fi­cer re­tires af­ter 35 years; Astel­las strat­e­gy ex­ec re­signs

Pharma channel feed

Yesterday

Cy­to­ki­net­ics suc­ceeds where Bris­tol My­ers failed in heart mus­cle dis­ease

Cy­to­ki­net­ics’ pill for a heart mus­cle dis­or­der called hy­per­trophic car­diomy­opa­thy could see its ad­dress­able mar­ket dou­ble af­ter it suc­ceed­ed in a piv­otal tri­al for an­oth­er form of the ...

READ MORE

Supreme Court re­stores abor­tion pill ac­cess by mail

Yesterday
Law

Mod­er­na in talks with FDA over post-mar­ket­ing Covid shot da­ta, with eyes on wider ac­cess

4 days ago
R&D
FDA+
latest in Pharma

FDA ap­proves Pfiz­er and Arv­inas' breast can­cer drug de­spite un­der­whelm­ing da­ta

4 days ago
FDA+

Sam­sung Bi­o­log­ics work­ers be­gin five-day strike over wage dis­putes 

4 days ago
Manufacturing

Court dis­miss­es part of Lil­ly law­suit against com­pounder Em­pow­er, but some claims can pro­ceed

5 days ago
Law
GLP-1 drugs

Supreme Court ques­tions how far gener­ics mak­ers can go when mar­ket­ing 'skin­ny la­bel' drugs

5 days ago
Law

Up­dat­ed: An­a­lysts fo­cus on three pipeline pro­grams in piv­otal year for Bris­tol My­ers

5 days ago
see latest stories

Marketing channel feed

Last week

Pfiz­er de­lays patent cliff for block­buster heart drug

Pfiz­er is staving off Vyn­damax com­pe­ti­tion for an­oth­er two years.

READ MORE

FDA warns Im­mu­ni­ty­Bio over mis­lead­ing pod­cast with Patrick Soon-Sh­iong

Last month
FDA+

FDA ap­proves GSK liv­er drug at cen­ter of Al­fasig­ma deal

Last month
FDA+
latest in Marketing

Ipsen pulls can­cer drug from mar­ket over safe­ty risks

Last month
Pharma
FDA+

Make way, Camzyos: Cy­to­ki­net­ics touts promis­ing ear­ly launch for ri­val heart drug

2 months ago
Pharma

No­vo Nordisk to slash We­govy list price in half in 2027 

2 months ago
Pharma

The FDA ad crack­down has phar­ma's at­ten­tion. But com­pa­nies aren't 'rad­i­cal­ly chang­ing course' — yet

2 months ago
Pharma

Take­da says it 'an­tic­i­pat­ed' top sell­er En­tyvio's in­clu­sion in IRA ne­go­ti­a­tions

3 months ago
Pharma
see latest stories

FDA+ channel feed

Yesterday

Ex­clu­sive: FDA search for new CBER head fo­cused on small group of fi­nal can­di­dates

The FDA has nar­rowed its search for a new leader of its Cen­ter for Bi­o­log­ics Eval­u­a­tion and Re­search to three or four fi­nal can­di­dates, ac­cord­ing to a per­son fa­mil­iar with the mat­ter.

READ MORE

Am­gen files up­date to Tavneos la­bel as FDA es­ca­lates push to with­draw 

4 days ago

FDA's on­col­o­gy ad­vi­sors vote against 'new par­a­dig­m' in As­traZeneca breast can­cer tri­al

5 days ago
R&D
latest in FDA+

House pan­el calls for ban­ning Chi­na da­ta from FDA drug tri­al ap­pli­ca­tions

5 days ago
China

FDA re­vives on­col­o­gy ad­vi­so­ry pan­el to de­bate As­traZeneca drugs

6 days ago
R&D
Pharma

FDA an­nounces re­al-time clin­i­cal tri­al da­ta ef­fort, with As­traZeneca and Am­gen as test cas­es

Last week
R&D
China

Up­dat­ed: FDA claims tri­al 'ma­nip­u­la­tion' taint­ed ap­proval of Chemo­Cen­tryx drug now owned by Am­gen

Last week
Pharma

No­var­tis pulls Plu­vic­to prostate can­cer la­bel ex­pan­sion fil­ing in the EU

Last week
Pharma
see latest stories

Manufacturing channel feed

5 days ago

XTL Bio to ac­quire psy­che­del­ic biotech; WuXi AppTec’s Q1 rev­enue rise

Plus, news about PCI Phar­ma:

READ MORE

No­var­tis un­veils North Car­oli­na fac­to­ry as fi­nal new build in $23B US ex­pan­sion

6 days ago
Pharma

As­traZeneca rekin­dles UK re­la­tion­ship, pledges £300M to ex­pand

6 days ago
Pharma
latest in Manufacturing

Dai­ichi Sankyo post­pones an­nu­al re­sults, stock dips

Last week
Pharma

Am­neal to buy a biosim­i­lar com­pa­ny; Sam­sung Bio work­ers protest

Last week

Ab­b­Vie's $1.4B North Car­oli­na man­u­fac­tur­ing site to fin­ish dur­ing Trump's term

Last week
Pharma

Bio­vac gets $108M back­ing for vac­cine fac­to­ry in South Africa

3 weeks ago
Pharma

MSF says Gilead­'s lenaca­pavir sup­ply 'not near­ly enough'; PolyPep­tide’s strate­gic re­view

3 weeks ago
see latest stories
A service from the Financial Times